Opinion

Video

Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • What are your thoughts on the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL, specifically related to sequencing and transplant eligibility?

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data

    Related Content